Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

Anker, Stefan D.; Ponikowski, Piotr; Clark, Andrew L.; Leyva, Francisco; Rauchhaus, Mathias; Kemp, Michael; Teixeira, Mauro Martins; Hellewell, Paul G.; Hooper, James; Poole‐Wilson, Philip A.; Coats, Andrew J.S.

doi:10.1053/euhj.1998.1446

Cited by 342 publications

(242 citation statements)

References 35 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…These patients have lower LVEF and worse exercise capacity in treadmill performance or 6MWT. However, our study population were younger (<55 years old with a mean of 37 years), and it means that as Anker et al 19 mentioned, the skeletal muscle is lost earlier in chronic diseases such as heart failure, and this muscle mass loss can be accelerated in heart failure independent of ageing process.…”

Section: Discussionmentioning

confidence: 86%

Muscle wasting in young patients with dilated cardiomyopathy

Hajahmadi

Shemshadi

Khalilipur

et al. 2017

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundMuscle wasting can be accelerated by chronic diseases such as heart failure and is one of the major causes of disability, morbidity, and mortality in this population. We aimed to investigate the incidence of muscle wasting and its associated factors in dilated cardiomyopathy patients younger than 55 years of age.MethodsBetween April 2014 and December 2015, all symptomatic patients with a diagnosis of non‐ischaemic dilated cardiomyopathy who were referred to heart failure clinic were included in our study.Dual energy X‐ray absorptiometry was used to evaluate body composition and identify muscle wasting. Muscle mass was calculated as the ratio of an individual's total lean mass of legs and arms (also called appendicular skeletal muscle) to their squared height (kg/m2). The muscle mass values of less than 5.45 kg/m2 for women and 7.26 kg/m2 for men were considered low.ResultsA total of 55 patients (32 male) were included. The mean (standard deviation) of age was 37.3 (10.1) years, and the mean of left ventricular ejection fraction was 21.4%. Most of the patients were in the New York Heart Association classes of II and II–III. Twenty‐six patients (47.3%) met criteria for muscle wasting. Patients with muscle wasting had lower left ventricular ejection fraction, lower 6‐min walk distance, and higher New York Heart Association function class and hospitalization rate.ConclusionsWe concluded that muscle wasting might be present in younger patients with heart failure, particularly in those who are in worse clinical condition.

show abstract

Section: Discussionmentioning

confidence: 86%

Muscle wasting in young patients with dilated cardiomyopathy

Hajahmadi

Shemshadi

Khalilipur

et al. 2017

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…Indeed, the values of IL-6 and sTNFR2 in subjects who died during follow up are comparable to patients with advanced stage congestive heart failure and patients with known cardiac cachexia. [25,26] Similar to other forms of non-malignant cachexia, this is a chronic hypercytokinemic cachexia with relative preservation of body weight and BMI in most patients. [27] For example, only 32 patients in this study had a BMI < 22 kg·m −2 , and no correlation existed between BMI and albumin.…”

Section: Discussionmentioning

confidence: 99%

An Integrated Biochemical Prediction Model of All-Cause Mortality in Patients Undergoing Lower Extremity Bypass Surgery for Advanced Peripheral Artery Disease

Owens

Kim

Gasper

et al. 2012

Journal of Surgical Research

View full text Add to dashboard Cite

Background-Patients with advanced peripheral artery disease (PAD) have a high prevalence of cardiovascular (CV) risk factors and shortened life expectancy. However, CV risk factors poorly predict midterm (<5 years) mortality in this population. This study was designed to test the hypothesis that baseline biochemical parameters would add clinically meaningful predictive information in patients undergoing lower extremity bypass.

show abstract

“…These tumor derived and locally produced cytokines interact with their cognate receptors on skeletal muscle to activate the NF-κB transcription factor, which induces atrophy by activating the ubiquitin proteasome system to degrade the sarcomere [1,[3][4][5]13,16,[24][25][26][27]29,38,49,56,66,74,80]. The significance of the convergence of these signaling pathways on NF-κB in cancerrelated muscle atrophy has been shown experimentally in a number of different ways.…”

Section: Introductionmentioning

confidence: 99%

Selective Inhibition of NF-kappa-B with NBD Peptide Reduces Tumor- Induced Wasting in a Murine Model of Cancer Cachexia In vivo

Wysong¹,

Asher

Yin

et al. 2011

JCST

View full text Add to dashboard Cite

Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation, which is seen in as many as 80% of patients with advanced malignancy. It accounts for an estimated 20-30% of all cancer-related deaths. The mechanism by which cancer induces skeletal muscle atrophy in cachexia involves tumor-derived cytokines, including TNFα, IL-1, and IL-6. Upon interaction with their unique receptors on skeletal muscle, these cytokines activate NF-kappaB, a transcription factor crucial for atrophy related sarcomere proteolysis to occur. The significance of NF-κB is highlighted in studies demonstrating that genetic inhibition of NF-κB ameliorates cancer-induced muscle loss in vivo. In the present study, we evaluate a selective NF-kappaB inhibitor (NBD peptide) which targets the IkappaB complex to prevent cancer-induced skeletal muscle atrophy in an established mouse model (C26 adenocarcinoma). We identified for the first time that NBD peptide can directly inhibit tumor-induced NFkappaB activation in skeletal muscle, resulting in a decrease loss of lean muscle. We also identified that NBD peptide reduces the expression of the tumor induced ubiquitin ligases MuRF-1 and MAFbx/Atrogin-1 necessary for atrophy. These findings highlight that NBD peptide may be a potential selective therapeutic agent for the treatment of cancer cachexia.

show abstract

Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure

Abstract: Peripheral loss of muscle tissue is a general finding in chronic heart failure. The wasting in cardiac cachexia affects all tissue compartments and is significantly related to neurohormonal and immunological abnormalities.

Cited by 342 publications

References 35 publications

Muscle wasting in young patients with dilated cardiomyopathy

Muscle wasting in young patients with dilated cardiomyopathy

An Integrated Biochemical Prediction Model of All-Cause Mortality in Patients Undergoing Lower Extremity Bypass Surgery for Advanced Peripheral Artery Disease

Selective Inhibition of NF-kappa-B with NBD Peptide Reduces Tumor- Induced Wasting in a Murine Model of Cancer Cachexia In vivo

Contact Info

Product

Resources

About